-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Beam Therapeutics Sets 2026 Strategic Priorities, Aligns With U.S. FDA On Potential Accelerated Approval Pathway For BEAM-302, And Ends 2025 With Preliminary Estimated $1.25B Cash

Benzinga·01/12/2026 07:13:04
Listen to the news
  • Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints
  • U.S. Biologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026
  • Expansion of Liver-targeted Genetic Disease Franchise Underway with New Program to be Announced in First Half of 2026